Grufity logoGrufity logo
StocksFundsSearch Filings

Aclaris Therapeutics Inc Stock Research

ACRS

8.79USD+0.09(+1.03%)Market Closed

Market Summary

USD8.79+0.09
Market Closed
1.03%

ACRS Alerts

ACRS Stock Price

ACRS RSI Chart

ACRS Valuation

Market Cap

590.7M

Price/Earnings (Trailing)

-6.14

Price/Sales (Trailing)

19.16

EV/EBITDA

-6.34

Price/Free Cashflow

-7.99

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

86.48%

EBT Margin

-292.11%

Return on Equity

-43.98%

Return on Assets

-34.14%

Free Cashflow Yield

-12.52%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

30.8M

Revenue Y/Y

73.98%

Revenue Q/Q

-67.39%

ACRS Earnings

Earnings (TTM)

-96.3M

Earnings Y/Y

-49.87%

Earnings Q/Q

-1.9%

Price Action

52 Week Range

5.7718.96
(Low)(High)

Last 7 days

6.0%

Last 30 days

-2.3%

Last 90 days

-31.2%

Trailing 12 Months

-39.3%

ACRS Financial Health

Current Ratio

10.55

ACRS Investor Care

Shares Dilution (1Y)

8.86%

Diluted EPS (TTM)

-1.44

Peers (Alternatives to Aclaris Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
409.0B
96.3B
-3.62% -9.57%
32.14
4.25
1.46% -35.83%
398.5B
27.7B
2.58% 47.15%
70.08
14.39
-5.56% -7.22%
272.8B
57.9B
-4.82% 28.79%
17.88
4.63
7.21% -8.11%
230.9B
93.0B
-0.23% -25.99%
7.36
2.3
0.56% 16.36%
150.1B
45.8B
-1.47% -11.26%
23.72
3.25
-2.37% 16.96%
MID-CAP
5.0B
4.6B
-12.00% -16.92%
-35.25
1.11
8.46% -29.07%
3.5B
1.5M
-8.84% 225.36%
-11.32
1.6K
-86.94% -16.59%
SMALL-CAP
1.8B
668.5M
-9.91% 19.28%
34.95
2.72
11.17% -29.04%
1.6B
596.3M
-7.75% -62.41%
-0.89
2.66
-3.41% -3791.67%
866.9M
271.5M
14.22% -13.24%
3.94
3.19
-31.50% -40.28%
666.4M
112.3M
-6.91% -41.08%
-4.29
5.94
7.69% 41.96%
590.7M
30.8M
-2.33% -39.30%
-6.14
19.16
378.90% -19.01%
536.4M
51.7M
11.79% 117.61%
-6.04
10.38
4.69% -299.77%
401.1M
478.9M
-31.81% -82.48%
-0.13
0.84
-31.50% -634.70%
94.1M
2.2B
-43.99% -88.43%
-0.03
0.04
-25.47% -292.77%

Financials for Aclaris Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue3.6%30,827,00029,752,00023,500,0006,141,0006,437,000
  S&GA Expenses10.7%27,824,00025,133,00024,930,00025,096,00024,891,000
  R&D Expenses10.6%86,094,00077,813,00070,843,00061,163,00050,281,000
EBITDA4.4%-86,111,000-90,063,000-90,022,000--
EBITDA Margin80.3%-2.89-14.67-13.99--
Earnings Before Taxes--86,908,000----
EBT Margin80.3%-2.92-14.80-14.12--
Net Income-10.8%-96,279,000-86,908,000-82,077,000-83,271,000-80,900,000
Net Income Margin16.4%-2.92-3.49-13.56-12.57-
Free Cahsflow-2.9%-68,172,000-66,227,000-68,922,000-61,431,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-9.8%230255268278227
  Current Assets-20.4%184232257259191
    Cash Equivalents-1.2%45.0045.0062.0068.0036.00
  Net PPE37.7%2.001.001.001.001.00
Liabilities-7.2%53.0057.0048.0042.0046.00
  Current Liabilities-16.8%18.0022.0020.0016.0017.00
Shareholder's Equity-10.5%177198220236180
  Retained Earnings-4.1%-710-682-654-634-614
  Additional Paid-In Capital0.8%888881876872795
Shares Outstanding0.8%67.0067.0067.0067.0062.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-8.0%-72,951-67,567-65,527-68,316-60,871
  Share Based Compensation29.7%19,49915,03914,07713,59113,731
Cashflow From Investing-32.7%8,49412,628750-38,139-62,386
Cashflow From Financing0.1%72,86772,82861,272124,332-

Risks for ACRS

What is the probability of a big loss on ACRS?

100%


Probability that Aclaris Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Aclaris Therapeutics stock will be more than 30% underwater in next one year.

91.2%


Probability that Aclaris Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACRS

Cumulative Returns on ACRS

-11.2%


7-Year Cumulative Returns

-13.6%


5-Year Cumulative Returns

81.9%


3-Year Cumulative Returns

What are the long-term rolling returns for ACRS?

FIve years rolling returns for Aclaris Therapeutics.

Annualized Returns

Which funds bought or sold ACRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-11.57
-118,866
98,925
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-0.78
-560,613
581,387
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-42.54
-519,000
217,000
-%
2023-05-18
JPMORGAN CHASE & CO
added
0.35
-3,264,000
3,472,000
-%
2023-05-16
JANE STREET GROUP, LLC
new
-
1,435,660
1,435,660
-%
2023-05-16
PERCEPTIVE ADVISORS LLC
sold off
-100
-5,374,510
-
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
230,371
230,371
-%
2023-05-15
Weiss Multi-Strategy Advisers LLC
new
-
477,000
477,000
0.01%
2023-05-15
SAMLYN CAPITAL, LLC
new
-
8,507,190
8,507,190
0.15%
2023-05-15
TWO SIGMA ADVISERS, LP
new
-
327,645
327,645
-%

1–10 of 38

Latest Funds Activity

Are funds buying ACRS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ACRS
No. of Funds

Aclaris Therapeutics News

InvestorsObserver
Aclaris Therapeutics to Participate in Two June Healthcare Investor ....
InvestorsObserver,
42 hours ago
GuruFocus.com
Aclaris Therapeutics to Partic.
GuruFocus.com,
42 hours ago
Investopedia
Zacks Investment Research
InvestorPlace

Schedule 13G FIlings of Aclaris Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2023
wellington management group llp
11.05%
7,372,601
SC 13G/A
Mar 16, 2023
biotechnology value fund l p
2.7%
1,794,881
SC 13G
Feb 14, 2023
rock springs capital management lp
5.94%
3,961,249
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
2.6%
1,732,725
SC 13G/A
Feb 13, 2023
foresite capital fund iv, l.p.
4.2%
2,808,034
SC 13G/A
Feb 06, 2023
wellington management group llp
8.22%
5,484,013
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
5,087,435
SC 13G/A
Apr 25, 2022
ra capital management, l.p.
7.1%
4,398,453
SC 13G
Feb 15, 2022
rock springs capital management lp
6.31%
3,861,347
SC 13G/A
Feb 14, 2022
venrock healthcare capital partners ii, l.p.
7.5%
4,563,962
SC 13G

ACRS Fair Value

Show Fair-Value

Recent SEC filings of Aclaris Therapeutics

View All Filings
Date Filed Form Type Document
Jun 02, 2023
8-K
Current Report
Jun 01, 2023
8-K
Current Report
May 08, 2023
10-Q
Quarterly Report
May 08, 2023
8-K
Current Report
May 08, 2023
S-8
Employee Benefits Plan
Apr 20, 2023
ARS
ARS
Apr 20, 2023
DEF 14A
DEF 14A
Apr 20, 2023
DEFA14A
DEFA14A
Apr 14, 2023
8-K
Current Report
Apr 10, 2023
PRE 14A
PRE 14A

Latest Insider Trading transactions for ACRS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
Manion Douglas J.
bought
49,532
7.8623
6,300
pres and ceo
2023-03-09
Manion Douglas J.
bought
50,277
7.735
6,500
pres and ceo
2023-03-03
Monahan Joseph
sold
-202,615
12.6342
-16,037
chief scientific officer
2023-03-03
Balthaser Kevin
sold
-11,289
12.6281
-894
chief financial officer
2023-03-03
Walker Neal
sold
-382,070
12.6346
-30,240
-
2023-03-02
Walker Neal
acquired
-
-
18,254
-
2023-03-02
Balthaser Kevin
sold
-12,289
12.289
-1,000
chief financial officer
2023-03-02
Monahan Joseph
sold
-183,024
12.3665
-14,800
chief scientific officer
2023-03-02
Balthaser Kevin
acquired
-
-
1,500
chief financial officer
2023-03-02
Walker Neal
sold
-358,588
12.3651
-29,000
-

1–10 of 50

Neal S. Walker
80
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Total revenue$ 2,528$ 1,453
Costs and expenses:  
Cost of revenue8081,155
Research and development22,58714,306
General and administrative8,7906,099
Licensing1,061 
Revaluation of contingent consideration(800)(1,200)
Total costs and expenses32,44620,360
Loss from operations(29,918)(18,907)
Other income, net1,758118
Net loss$ (28,160)$ (18,789)
Net loss per share, basic$ (0.42)$ (0.31)
Net loss per share, diluted$ (0.42)$ (0.31)
Weighted average common shares outstanding, basic66,872,77861,431,026
Weighted average common shares outstanding, diluted66,872,77861,431,026
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities, net of tax of $0$ 543$ (748)
Total other comprehensive income (loss)543(748)
Comprehensive loss(27,617)(19,537)
Contract research  
Revenues:  
Total revenue8891,221
Licensing  
Revenues:  
Total revenue$ 1,639202
Other  
Revenues:  
Total revenue $ 30

ACRS Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 44,722$ 45,277
Short-term marketable securities126,081172,294
Accounts receivable, net686484
Prepaid expenses and other current assets12,87213,495
Total current assets184,361231,550
Marketable securities33,60212,242
Property and equipment, net1,5131,099
Intangible assets6,9546,973
Other assets3,2752,732
Total assets229,705254,596
Current liabilities:  
Accounts payable8,19010,351
Accrued expenses7,2638,701
Current portion of lease liabilities603684
Discontinued operations2,2022,202
Total current liabilities18,25821,938
Other liabilities1,9701,570
Contingent consideration32,30033,100
Deferred tax liability367367
Total liabilities52,89556,975
Commitments and contingencies (Note 14)
Stockholders' Equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.00001 par value; 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 67,206,025 and 66,688,647 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively11
Additional paidin capital887,638880,832
Accumulated other comprehensive loss(354)(897)
Accumulated deficit(710,475)(682,315)
Total stockholders' equity176,810197,621
Total liabilities and stockholders' equity$ 229,705$ 254,596